| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | gABRa4 |
| Uniprot No | P48169 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 36-258aa |
| 氨基酸序列 | QNQKEEKLCTENFTRILDSLLDGYDNRLRPGFGGPVTEVKTDIYVTSFGPVSDVEMEYTMDVFFRQTWIDKRLKYDGPIEILRLNNMMVTKVWTPDTFFRNGKKSVSHNMTAPNKLFRIMRNGTILYTMRLTISAECPMRLVDFPMDGHACPLKFGSYAYPKSEMIYTWTKGPEKSVEVPKESSSLVQYDLIGQTVSSETIKSITGEYIVMTVYFHLRRKMGY |
| 预测分子量 | 41.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与GABRA4重组蛋白相关的文献概览：
---
1. **文献名称**：*Expression and functional characterization of recombinant α4β2δ GABAA receptors in HEK293 cells*
**作者**：Boll, S., et al.
**摘要**：本研究利用HEK293细胞成功表达重组α4β2δ GABAA受体，发现δ亚基的共表达显著增强α4β2受体对神经类固醇的敏感性，并改变苯二氮䓬类药物的结合特性，提示α4亚基在抑制性突触外受体功能中的关键作用。
---
2. **文献名称**：*Altered GABAA receptor α4 subunit expression in epilepsy: A role for synaptic inhibition*
**作者**：Lucas, C.R., et al.
**摘要**：通过构建重组GABRA4蛋白模型，结合癫痫小鼠脑组织分析，发现GABRA4在癫痫发作后表达上调，可能与突触外GABA受体的重塑相关，进而影响抑制性神经传递的代偿机制。
---
3. **文献名称**：*Structural determinants of benzodiazepine binding kinetics in α4/6-subunit-containing GABAA receptors*
**作者**：Kaur, N., et al.
**摘要**：利用重组α4β3γ2 GABAA受体进行结构功能研究，揭示α4亚基的跨膜结构域(如M3区域)是调控苯二氮䓬类药物结合动力学的关键位点，为靶向α4亚基的药物设计提供理论依据。
---
**备注**：上述文献为模拟示例，实际研究中建议通过PubMed或Web of Science检索最新论文(关键词：GABRA4 recombinant, GABA receptor alpha4 expression)。
**Background of gABRa4 Recombinant Protein**
The gamma-aminobutyric acid type A (GABAA) receptor is a ligand-gated ion channel central to inhibitory neurotransmission in the mammalian central nervous system. It mediates fast synaptic inhibition by allowing chloride ion influx upon binding GABA, leading to neuronal hyperpolarization. The receptor is a heteropentamer, typically composed of combinations of α, β, γ, δ, ε, θ, or π subunits. Among these, the α4 subunit (encoded by *GABRA4*) is notable for its unique expression patterns and functional properties.
The α4 subunit is predominantly expressed in extrasynaptic regions of specific brain areas, such as the thalamus, hippocampus, and cortex, where it contributes to the formation of receptors with high sensitivity to GABA and neurosteroids. These receptors play roles in tonic inhibition, regulating neuronal excitability, and are implicated in physiological processes like sleep, anxiety, and seizure modulation. Dysregulation of α4-containing GABAA receptors has been linked to neurological disorders, including epilepsy, insomnia, and neuropathic pain.
The recombinant gABRa4 protein is engineered to enable detailed structural and functional studies. Produced via heterologous expression systems (e.g., mammalian or insect cells), it allows researchers to isolate α4 subunit interactions, screen for subunit-specific drugs, or investigate mechanisms underlying receptor trafficking and pharmacology. Recombinant technology ensures high purity, consistency, and scalability compared to native protein extraction, overcoming challenges like low natural abundance and subunit heterogeneity.
Studies utilizing gABRa4 recombinant protein have advanced understanding of GABAergic signaling plasticity, neurosteroid modulation, and the development of targeted therapies for neurological conditions. Its application continues to drive discoveries in neuropharmacology and receptor biology.
×
